- Home
- DATS vs SLXN Comparison
DATS vs SLXN Comparison
Compare DATS & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- SLXN
- Stock Information
- Founded
- DATS 2014
- SLXN 2008
- Country
- DATS United States
- SLXN Israel
- Employees
- DATS N/A
- SLXN N/A
- Industry
- DATS Computer Software: Prepackaged Software
- SLXN
- Sector
- DATS Technology
- SLXN
- Exchange
- DATS Nasdaq
- SLXN NYSE
- Market Cap
- DATS 5.2M
- SLXN 5.2M
- IPO Year
- DATS 2021
- SLXN N/A
- Fundamental
- Price
- DATS $1.74
- SLXN $2.44
- Analyst Decision
- DATS
- SLXN Strong Buy
- Analyst Count
- DATS 0
- SLXN 1
- Target Price
- DATS N/A
- SLXN $1.00
- AVG Volume (30 Days)
- DATS 392.8K
- SLXN 1.1M
- Earning Date
- DATS 11-14-2024
- SLXN 02-21-2025
- Dividend Yield
- DATS N/A
- SLXN N/A
- EPS Growth
- DATS N/A
- SLXN N/A
- EPS
- DATS N/A
- SLXN N/A
- Revenue
- DATS $515.00
- SLXN N/A
- Revenue This Year
- DATS N/A
- SLXN N/A
- Revenue Next Year
- DATS N/A
- SLXN N/A
- P/E Ratio
- DATS N/A
- SLXN N/A
- Revenue Growth
- DATS N/A
- SLXN N/A
- 52 Week Low
- DATS $1.01
- SLXN $0.21
- 52 Week High
- DATS $4.13
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- DATS 47.83
- SLXN N/A
- Support Level
- DATS $1.61
- SLXN N/A
- Resistance Level
- DATS $1.82
- SLXN N/A
- Average True Range (ATR)
- DATS 0.16
- SLXN 0.00
- MACD
- DATS -0.03
- SLXN 0.00
- Stochastic Oscillator
- DATS 23.21
- SLXN 0.00
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts, even after they are sent.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.